Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

February 25, 2020

New treatment for men with non-metastatic castration resistant prostate cancer approved in Canada

Read more
February 13, 2020

Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer

Full data to be presented at upcoming scientific meeting Read more
December 03, 2019

Bayer to help young leaders fight food insecurity

Young Canadian leaders return from Youth Ag Summit in Brazil with global perspective for tackling the UN Sustainable Development Goals Read more
November 15, 2019

Bayer responds to decision by the Institut national d’excellence en santé et en services sociaux (INESSS) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Read more
November 06, 2019

Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Read more
October 29, 2019

Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program

Read more
October 22, 2019

4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM

Read more
October 16, 2019

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer

79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications / Similar ORR of 75% in patients with brain metastases1, adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years1 / Largest dataset with longest follow-up of any TRK inhibitor illustrates favourable safety profile across ages and tumour types Read more
October 02, 2019

Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program

67 Canadian students pursuing post-secondary education in agriculture and food-related disciplines Read more
September 30, 2019

European Society of Cardiology recommends (rivaroxaban) XARELTO® 2.5 mg plus acetylsalicylic acid for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes

Read more